Please assess the completion status of the following clinical trial:

Trial Title: A Phase 1 Dose Escalation Study of AMG 780 in Adult Subjects With Advanced Solid Tumors

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women ≥ 18 years old~* Must have a pathologically documented, and definitely diagnosed, advanced solid tumor that is refractory to standard treatment, or for which no curative therapy is available, or for subjects who refuse standard therapy~* Measurable disease by RECIST criteria~* Must be able to undergo MRI evaluation~* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2~* Competent to sign and date an Institutional Review Board approved informed consent form~Exclusion Criteria:~* Presence of untreated or symptomatic primary central nervous system tumors or metastases~* Presence of leukemia or myelodysplastic syndrome~* Subjects with head and neck cancer~* Previous hematopoietic stem cell transplant (allogeneic)~* Unresolved hematological toxicities \> grade 1 with the exception of grade 2 lymphopenia and non-hematological toxicities \> grade 1, excluding alopecia and grade 2 neuropathy, from prior anti-cancer therapy~* Myocardial infarction within 1 year before study day 1, or unstable or uncontrolled disease/condition related to or affecting cardiac function~* History of stroke, arterial or venous thrombosis, or pulmonary embolism within 1 year before study~* Active peripheral vascular disease~* History of bleeding diathesis~* History of pulmonary hemorrhage or gross hemoptysis within 6 months before study~* Known history of adrenal hemorrhage~* Known positive test for human immunodeficiency virus infection, or active hepatitis B or hepatitis C~* Major surgery within 1 month before study~* Prior treatment with any agent targeting the angiopoietin-Tie2 signaling pathway~* Concurrent antitumor treatment, except Lupron for subjects with prostate cancer and selective estrogen receptor modulators (SERMS) for subjects with breast cancer, within 4 weeks (6 weeks for nitrosoureas or mitomycin) before study day 1~* Known sensitivity to mammalian-derived products, bacterially-produced proteins, or any of the products to be administered during dosing~* Investigational agent within 30 days before study~* Pregnant (eg, positive urine test) or breastfeeding~* Subjects of childbearing potential, or subject who has a partner of childbearing potential, and is not using highly effective contraceptive precautions

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): Dose Escalation
- B (Type: EXPERIMENTAL): Dose Expansion

Based on this trial design, predict the completion outcome and termination type (if applicable).